Optimal Interpretation of FDG PET in the Diagnosis, Staging and Management of Pancreatic Carcinoma

• Published in: The Journal of nuclear medicine (1978) Vol. 40; no. 11; pp. 1784 - 1791
• Main Authors: Delbeke, Dominique, Rose, D. Michael, Chapman, William C, Pinson, C. Wright, Wright, J. Kelly, Beauchamp, R. Daniel, Shyr, Yu, Leach, Steven D
• Format: Journal Article
• Language: English
• Published: Reston, VA Soc Nuclear Med 01.11.1999; Society of Nuclear Medicine
• Subjects: Adenocarcinoma - diagnostic imaging; Adenocarcinoma - epidemiology; Biological and medical sciences; Blood Glucose - analysis; Digestion. Liver. Biliary tract. Spleen. Pancreas; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Gastroenterology. Liver. Pancreas. Abdomen; Humans; Investigative techniques, diagnostic techniques (general aspects); Liver. Biliary tract. Portal circulation. Exocrine pancreas; Male; Medical sciences; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms - diagnostic imaging; Pancreatic Neoplasms - epidemiology; Predictive Value of Tests; Radionuclide investigations; Radiopharmaceuticals; Sensitivity and Specificity; Tomography, Emission-Computed; Tomography, X-Ray Computed; Tumors; Radionuclide study; Human; Evaluation; Indication; Stage classification; Malignant tumor; Treatment; Surveillance; Decision aid; Digestive diseases; Diagnosis; Pancreas; Pancreatic disease; Positron; Emission tomography
• ISSN: 0161-5505; 1535-5667

This study had two purposes: to optimize the semiquantitative interpretation of 18F-fluorodeoxyglucose (FDG) PET scans in the diagnosis of pancreatic carcinoma by analyzing different cutoff levels for the standardized uptake value (SUV), with and without correction for serum glucose level (SUV(gluc)); and to evaluate the usefulness of FDG PET when used in addition to CT for the staging and management of patients with pancreatic cancer. Sixty-five patients who presented with suspected pancreatic carcinoma underwent whole-body FDG PET in addition to CT imaging. The PET images were analyzed visually and semiquantitatively using the SUV and SUV(gluc). The final diagnosis was obtained by pathologic (n = 56) or clinical and radiologic follow-up (n = 9). The performance of CT and PET at different cutoff levels of SUV was determined, and the impact of FDG PET in addition to CT on patient management was reviewed retrospectively. Fifty-two patients had proven pancreatic carcinoma, whereas 13 had benign lesions, including chronic pancreatitis (n = 10), benign biliary stricture (n = 1), pancreatic complex cyst (n = 1) and no pancreatic pathology (n = 1). Areas under receiver operating characteristic curves were not significantly different for SUV and SUV(gluc). Using a cutoff level of 3.0 for the SUV, FDG PET had higher sensitivity and specificity than CT in correctly diagnosing pancreatic carcinoma (92% and 85% versus 65% and 61%). There were 2 false-positive PET (chronic pancreatitis, also false-positive with CT) and 4 false-negative PET (all with true-positive CT, abnormal but nondiagnostic) examinations. There were 5 false-positive CT (4 chronic pancreatitis and 1 pancreatic cyst) and 18 false-negative CT (all with true-positive FDG PET scans) examinations. FDG PET clarified indeterminate hepatic lesions or identified additional distant metastases (or both) in 7 patients compared with CT. Overall, FDG PET altered the management of 28 of 65 patients (43%). FDG PET is more accurate than CT in the detection of primary tumors and in the clarification and identification of hepatic and distant metastases. The optimal cutoff value of FDG uptake to differentiate benign from malignant pancreatic lesions was 2.0. Correction for serum glucose did not significantly improve the accuracy of FDG PET. Although FDG PET cannot replace CT in defining local tumor extension, the application of FDG PET in addition to CT alters the management in up to 43% of patients with suspected pancreatic cancer.